Nkarta, Inc. Common Stock
NKTXStock
$2.60+46.15%52W
Market Cap$186.02M
P/E—
Div yield—
Beta0.91
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)19.67%
Price vs S&P 500 (4W)0.93%
VGM Score61.25
Market Capitalization$186.02M
Earnings Surprise History
Q1 26-0.37est. -0.38
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.15
4.25
4.27
4.30
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NKTXNkarta, Inc. Common Stock | — | — | B | $2.60 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Nkarta is a clinical-stage biopharmaceutical company developing off-the-shelf allogeneic natural killer (NK) cell therapies for cancer treatment. The company combines proprietary NK cell expansion technology with engineered cell recognition capabilities to enhance therapeutic targeting and persistence. This approach aims to generate an abundant supply of engineered NK cells that can identify and eliminate cancer cells while triggering durable immune responses.